New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4) -

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Information type: Randomised controlled trials
Source: Diabetes Care
Specialities: Diabetes
Summary
6-month RCT (n=549) found change in HbA1c was equivalent in Glargine 300 and 100 groups (difference, 0.04%) and Gla-300 was thus considered non-inferior. Hypoglycaemia (HG) did not differ, except for first 8 weeks when nocturnal confirmed/severe HG was lower with Gla-300.
UKMi comment
Insulin glargine U300 (Toujeo®) is a new formulation based on the insulin glargine molecule, but with a reduced redissolution rate following subcutaneous administration, resulting in a flatter and more prolonged pharmacokinetic/dynamic profile than Lantus®. It was approved in the EU for the treatment of diabetes in April 2015.
Related links: